Cervomed Reports Promising Outcomes In Dementia Study

$CRVO

CervoMed Inc. (NASDAQ:CRVO) has recently announced results from the extension phase of its Phase 2b clinical study, RewinD-LB, which focuses on treating dementia with Lewy bodies (DLB) using the investigational drug neflamapimod. The study revealed that the new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated significant improvement in both the primary and key secondary endpoints.

Specifically, the Clinical Dementia Rating Sum of Boxes (CDR-SB) and the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (CGIC) showed enhancements compared to previous capsule formulations and placebo. Moreover, the incidence of falls, a common and dangerous complication in DLB patients, was notably lower among participants who received the new formulation of the drug during the study.

The extension phase of the RewinD-LB study involved 149 participants who continued the treatment after the initial 16-week double-blind phase. Remarkably, the adherence to the treatment and the completion rate of this phase were high, with over 87% of participants who received the old capsules and 91.5% of those who received the new capsules completing the first 16 weeks of the extension phase.

CervoMed’s approach in this trial was particularly rigorous, utilizing a linear Mixed-effects Model for Repeated Measures to analyze the data, which lends robustness to the findings.
The implications of these findings are profound. DLB is the third most common degenerative disease of the brain, following Alzheimer’s and Parkinson’s diseases.

Patients with DLB experience a significant decline in cognitive abilities and motor functions, leading to increased healthcare costs and caregiver distress. The potential of neflamapimod to make a meaningful difference in the lives of DLB patients is a beacon of hope for those affected by this challenging condition. Looking ahead, CervoMed plans to engage with regulatory authorities to discuss the progression to a Phase 3 study and explore the steps necessary for potential approval of neflamapimod.

**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**